ClinicalTrials.gg
CompletedNCT02889302Updated Dec 14, 2018

An Additional Confirmatory Study of KPS-0373 in Patients With Spinocerebellar Degeneration (SCD)

A Phase 3 interventional study of KPS-0373 and Placebo in Spinocerebellar Degeneration, sponsored by Kissei Pharmaceutical Co., Ltd.. Completed at 1 site in Japan. Open to participants aged 20 Years and older. Per ClinicalTrials.gov, last updated 2018-12-14.

Sponsored by Kissei Pharmaceutical Co., Ltd. · Phase 3, Interventional, and Treatment

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Phase 3
Study type
Interventional
Enrollment
203
Allocation
Randomized
Ages
20 Years and older
Sex
All
01

Where this study stands

Counted across the records on this site · 2026-11-16

Among 11 studies in Spinocerebellar Degenerations with a site in Japan — none open to participants now, 1 under way, 1 of them phase 3. Spinocerebellar Degenerations · Japan.

Started
2016
the only one that year
Phase 3
7 of 11
none open now
Registered
8th of 11
by date
Lead sponsor
9 of 11
Kissei Pharmaceutical Co., Ltd.

Among the 11 studies in Spinocerebellar Degenerations with a site in Japan, this one is the only one that started in 2016, is one of 7 in phase 3, and was the 8th registered.

Spinocerebellar Degenerations

49 studies on the registry are indexed under Spinocerebellar Degenerations; 15 are open to participants now.

Browse Spinocerebellar Degenerations studies →

Open to participants now

None of the 11 studies in Spinocerebellar Degenerations with a site in Japan is open now. The open studies under Spinocerebellar Degenerations, anywhere →

Who these studies take

Of the 9 Spinocerebellar Degenerations studies recruiting now, 5 set no upper age limit and 3 stop at 75 or younger; 4 take children under 18; 1 takes healthy volunteers.

This study: 20 Years and older · all sexes · no healthy volunteers.

The full table on the hub →

This tab as a report to print or save as PDF → With an account.

Was this useful?
Download CSVNarrow it in search →With an account: the 11 studies in Spinocerebellar Degenerations with a site in Japan as a file.
02

Study summary

The purpose of this study is to investigate the superiority of KPS-0373 to placebo, and evaluate the safety of KPS-0373 in SCD patients.

03

Conditions studied

  • Spinocerebellar Degeneration
04

Who can participate

Ages eligible
20 Years and older
Sexes eligible
All
Accepts healthy volunteers
No

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  • Japanese SCD patients with mild to moderate ataxia

Exclusion criteria

Exclusion Criteria:

  • Patients with secondary ataxia
  • Patients with hepatic, renal, or cardiovascular dysfunction
Terms in these criteria, in plain language(1)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

Clinically significant

Judged by the study doctor to matter for your health or for the study. It is a doctor’s decision, so ask the study team if you are unsure whether something counts.

05

Study design

Phase
Phase 3
Primary purpose
Treatment
Allocation
Randomized
Intervention model
Parallel assignment
Masking
Double (Participant, Investigator)
Enrollment
203 participants (actual)

Study arms

  • Experimental
    KPS-0373

    Drug: KPS-0373

  • Placebo comparator
    Placebo

    Drug: Placebo

Interventions

06

What researchers measure

Primary outcomes

  1. SARA (Scale for the Assessment and Rating of Ataxia)

    The change in the SARA total score at the time of final evaluation

    Time frame: 24 weeks

Secondary outcomes

  1. SF-8(QOL)

    Time frame: 24 weeks

07

Study locations

1 site
  • Multiple Locations, Japan
08

References and documents

Publications

  • Nishizawa M, Onodera O, Hirakawa A, Shimizu Y, Yamada M; Rovatirelin Study Group. Effect of rovatirelin in patients with cerebellar ataxia: two randomised double-blind placebo-controlled phase 3 trials. J Neurol Neurosurg Psychiatry. 2020 Mar;91(3):254-262. doi: 10.1136/jnnp-2019-322168. Epub 2020 Jan 14. PubMed 31937586 ↗
09

Timeline

Tracking since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reached

Ran from Nov 2016 to primary completion in Mar 2018, 16 months.

How these figures are worked out, and which studies are left out of them.

Registered
Aug 31, 2016
First posted
Sep 5, 2016
StartActual
Nov 15, 2016
Primary completionActual
Mar 2018
CompletionActual
Mar 2018
Last update
Dec 14, 2018
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
No changes since tracking began. The registry record was last updated on Dec 14, 2018, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
10

Registry details

Key details

Study ID
NCT02889302
Responsible party
Sponsor
First posted
Sep 5, 2016
Start date
Nov 15, 2016
Primary completion
Mar 2018
Completion
Mar 2018
Last update
Dec 14, 2018

Study contacts

Nobuo Kanai
study director
View the source record on ClinicalTrials.gov ↗

Not currently enrolling

This study is completed, as verified in Dec 2018. You cannot join it, but the record below documents what was studied.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Studies of the drug tested here: Rovatirelin

Start the discussion